Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Editor’s Choice for September 2018

Published: 28 Sep 2018

Views: 1125

Rating:

Save

Prof Gordon McVie - Founding Editor, ecancer

	Journal
	Special Issue: The microbiome – a novel paradigm in oncology research
	Conference Report: Highlights from the 2018 WIN Symposium, 25–26 June 2018, Paris: designing the future of precision oncology
	Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas
	Case Report: Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation
	Video
	WIN Symposium 2018
	R4HC
	Education
	Latin American Palliative Care Course

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

The current status of multiple myeloma diagnosis and treatment

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

The use of IORT at Universitätsmedizin Mannheim hospital

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Choosing Wisely to mitigate financial toxicity in cancer care in Africa

Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely to mitigate financial toxicity in cancer care in Africa ( Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

Tumour-infiltrating lymphocyte treatment for advanced melanoma

Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Tumour-infiltrating lymphocyte treatment for advanced melanoma ( Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

More from ecancer